Elinzanetant

Elinzanetant, sold under the brand name Lynkuet, is an orally active small-molecule neurokinin/tachykinin NK₁ receptor and NK₃ receptor antagonist which is under development by Bayer, GlaxoSmithKline, and Nerre Therapeutics for the treatment of hot flashes and sex hormone disorders.^[4] It has been found to relieve hot flashes in postmenopausal women and to dose-dependently suppress luteinizing hormone, estradiol, and progesterone levels in premenopausal women.^[4][5]

Elinzanetant

Clinical data
Trade names	Lynkuet
Other names	BAY-3427080; GSK-1144814; NT-814
Routes of administration	Oral administration
ATC code	None
Legal status
Legal status	CA: ℞-only[1][2] UK: POM (Prescription only)[3]
Identifiers
IUPAC name N-[6-[(7S,9aS)-7-(hydroxymethyl)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethylpropanamide
CAS Number	929046-33-3
PubChem CID	16063568
ChemSpider	17223178
UNII	NZW2BOW35N
KEGG	D12123
CompTox Dashboard (EPA)	DTXSID101337049
Chemical and physical data
Formula	C33H35F7N4O3
Molar mass	668.657 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(C=CC(=C1)F)C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4C[C@H]5COCCN5C[C@H]4CO
InChI InChI=1S/C33H35F7N4O3/c1-19-9-23(34)5-6-26(19)27-13-29(44-16-25-18-47-8-7-43(25)15-24(44)17-45)41-14-28(27)42(4)30(46)31(2,3)20-10-21(32(35,36)37)12-22(11-20)33(38,39)40/h5-6,9-14,24-25,45H,7-8,15-18H2,1-4H3/t24-,25-/m0/s1 Key:DWRIJNIPBUFCQS-DQEYMECFSA-N

Elinzanetant is a non-hormonal, selective, neurokinin 1 (NK-1) and 3 (NK-3) receptor antagonist.^[6] By blocking NK-1 and NK-3 receptors signalling, elinzanetant is postulated to normalize neuronal activity involved in thermo- and sleep regulation in the hypothalamus.^[6]

Medical uses

Elinzanetant is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause.^[7]

Society and culture

Legal status

In September 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Lynkuet, intended for the treatment of moderate to severe vasomotor symptoms (hot flushes).^[6] The applicant for this medicinal product is Bayer AG.^[6]

Names

Elinzanetant is the international nonproprietary name.^[8]

Elinzanetant is sold under the brand name Lynkuet.